Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06361758
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-08
Brief Title:
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Shanghai Zhongshan Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Hepatocellular Carcinoma |
Keywords:
| Name | View |
|---|---|
| cadonilimab anti PD-1CTLA-4 bispecific antibody | View |